Last reviewed · How we verify

Prevention of deep vein thrombosis — Treatment Landscape & Competitive Intelligence

Prevention of deep vein thrombosis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prevention of deep vein thrombosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Savaysa edoxaban Daiichi Sankyo Inc Factor Xa Inhibitor Coagulation factor X 2015-01-01
Xarelto rivaroxaban Johnson & Johnson Direct Factor Xa Inhibitor Factor Xa (FXa) 2011-01-01
Pradaxa dabigatran etexilate Generic (originally Boehringer Ingelheim) Direct oral anticoagulant (DOAC) — direct thrombin inhibitor Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone] 2010-10-19
Pradaxa dabigatran-etexilate Boehringer Ingelheim Direct thrombin inhibitor Thrombin (serine protease) 2010-01-01
Revasc DESIRUDIN Marathon Pharms Llc Anti-coagulant Prothrombin 2003-01-01
Arixtra FONDAPARINUX Mylan Ireland Ltd Factor Xa Inhibitor Coagulation factor X 2001-01-01
Coumadin warfarin Generic (originally Wisconsin Alumni Research Foundation) Vitamin K antagonist (anticoagulant) Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7 1954-01-01
Heparin Sodium In Plastic Container HEPARIN Merck & Co. Anti-coagulant Antithrombin-III 1939-01-01
Heparin Sodium In Plastic Container Heparin Sodium Fresenius Kabi Anticoagulant Antithrombin III, Coagulation Factors Xa and IIa 1939-01-01
Arixtra Arixtra LifeBridge Health Antithrombin-III, Coagulation factor X

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Boehringer Ingelheim · 1 drug in Prevention of deep vein thrombosis
  2. Daiichi Sankyo Inc · 1 drug in Prevention of deep vein thrombosis
  3. Fresenius Kabi · 1 drug in Prevention of deep vein thrombosis
  4. Generic (originally Boehringer Ingelheim) · 1 drug in Prevention of deep vein thrombosis
  5. Generic (originally Wisconsin Alumni Research Foundation) · 1 drug in Prevention of deep vein thrombosis
  6. Johnson & Johnson · 1 drug in Prevention of deep vein thrombosis
  7. LifeBridge Health · 1 drug in Prevention of deep vein thrombosis
  8. Marathon Pharms Llc · 1 drug in Prevention of deep vein thrombosis
  9. Merck & Co. · 1 drug in Prevention of deep vein thrombosis
  10. Mylan Ireland Ltd · 1 drug in Prevention of deep vein thrombosis
  11. Pfizer Inc. · 1 drug in Prevention of deep vein thrombosis
  12. University Hospital, Montpellier · 1 drug in Prevention of deep vein thrombosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of deep vein thrombosis:

Cite this brief

Drug Landscape (2026). Prevention of deep vein thrombosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-deep-vein-thrombosis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing